Nearly 1 in 3 U.S. adults—an estimated 59 million—has high blood pressure. High blood pressure or hypertension is a major risk factor for heart disease, stroke, congestive heart failure and kidney disease. Despite treatment with multiple blood pressure medications, many people are still searching for a way to control their blood pressure. This week, a Wall Street Journal article discussed a clinical trial of a new therapy called renal denervation that could help revolutionize how doctors treat patients with uncontrolled blood pressure.
Keith Benzuly, MD, a cardiologist and the principal investigator of this trial at Northwestern’s Bluhm Cardiovascular Institute, spoke with the Wall Street Journal about how the trial focuses on patients with high blood pressure who don’t benefit from these hypertension medications. Benzuly commented, “They don’t have any other identifiable, treatable causes of high blood pressure. That has been frustrating for patients for years.”
To learn more, view the full Wall Street Journal article.